Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral edaravone (FAB122) versus placebo in amyotrophic lateral sclerosis
NL-OMON54334Phase 3Active, not recruiting
- Sponsor
- Ferrer
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of edaravone in amyotrophic lateral sclerosis (ALS), sponsored by Ferrer. Primary endpoint: Change from baseline in ALSFRS-R total score at 48 weeks. Started Jan 2022; status: active, not recruiting.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON54334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54334.